Chondral Defect
2
Pipeline Programs
1
Companies
2
Clinical Trials
2 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
2
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
1 companies ranked by most advanced pipeline stage
VericelCAMBRIDGE, MA
2 programs2
MACIPhase 31 trial
autologous cultured chondrocytes on porcine collagen membranePhase 31 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
Vericelautologous cultured chondrocytes on porcine collagen membrane
VericelMACI
Clinical Trials (2)
Total enrollment: 354 patients across 2 trials
A Study of MACI in Patients Aged 17 to 65 Years With Symptomatic Chondral or Osteochondral Defects of the Ankle
Start: Mar 2026Est. completion: Jul 2030309 patients
Phase 3Recruiting
A Study of MACI in Patients Aged 10 to 17 Years With Symptomatic Chondral or Osteochondral Defects of the Knee
Start: Oct 2018Est. completion: Jun 202745 patients
Phase 3Recruiting
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 late-stage (Phase 3) programs — potential near-term approvals
2 actively recruiting trials targeting 354 patients
1 companies competing in this space